Impact Award
The FAST Impact Award funds innovative translational research to advance therapies for Angelman syndrome from pre-clinical stages to IND application readiness.
Funder: Foundation for Angelman Syndrome Therapeutics (FAST)
Due Dates: Rolling
Funding Amounts: Up to $1,000,000 per year for 1–2 years; larger budgets considered with justification.
Summary: Supports ambitious translational research moving Angelman syndrome therapies from pre-clinical development to IND application readiness.
Key Information: Letter of Intent (LOI) required prior to full application; only nonprofit institutions eligible.
Description
The Foundation for Angelman Syndrome Therapeutics (FAST) Impact Award provides substantial funding for translational research projects that advance therapies for Angelman syndrome from pre-clinical stages through preparation for Investigational New Drug (IND) applications. The program prioritizes innovative approaches, including repurposing existing therapies, and strongly emphasizes pharmacological, biologic, disease-modifying, gene-editing, and gene replacement strategies that directly target the underlying mechanisms of Angelman syndrome. By supporting both pre-clinical and clinical research with strong scientific rationale, the award aims to accelerate clinical readiness and reduce risks in developing new treatments for the Angelman syndrome community.
